Molecular Targeted Therapy in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 667
Special Issue Editor
Special Issue Information
Dear Colleagues,
Paul Ehrlich proposed the "magic bullet" concept in the 1890s, aiming that treatment could be specific to the target without toxicity to the healthy cells. With the advance in cancer biology, especially the DNA changes and proteins that drive cancer, this concept has recently been implemented efficiently in cancer treatment.
Molecular targeted cancer therapy consists mainly of small molecule inhibitors or monoclonal antibodies that inhibit the signal transduction pathways involved in growth, proliferation, and survival. Immune checkpoint inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), antibody‒drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT) are some of the recent molecular targeted cancer therapies.
Although molecular targeted therapy has achieved remarkable survival benefits in many types of cancer, they are not for every cancer patient and cause side effects and toxicity in some cases, in addition to drug resistance.
This Special Issue aims to receive relevant contributions and recent insight into identifying druggable targets and discovering new drugs with different chemical entities or modes of action. We also seek contributions to finding or developing cancer small molecule inhibitors with higher specificity to cancer cells to increase efficacy and minimize toxicity. We are also keen to collect contributions to the patient microbiome's role in molecular targeted cancer therapy, such as cancer development, cancer progression and metastasis, and drug resistance and toxicity.
Prof. Dr. Sayed K. Goda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular targeted therapy
- signal transduction inhibitors
- small molecules of cancer drugs
- targeted cancer therapy
- host microbiome in cancer-targeted therapy
- anticancer drugs
- cancer drug resistance
- solid tumors
- monoclonal antibodies in cancer therapy
